Efek Samping Hipoglikemi yang Dialami oleh Pasien Geriatri yang Berisiko Sindrom Metabolik
Side Effects of Hypoglycemic Experienced by Geriatric Patients Who are at Risk of Metabolic Syndrome
DOI:
https://doi.org/10.25026/jsk.v4i4.1282Keywords:
Keywords: Metabolic syndrome, Hypoglycemia, Hospital, Yogyakarta.Abstract
Metabolic syndrome is a collection of symptoms of metabolic problem of the body with a several diseases. This study was to observe the relationship of geriatric patients characteristics versus clinical conditions (blood pressure, blood glucose, cholesterol and triglyceride) and find out which drugs are most often used. This research was conducted in 3 hospitals in Yogyakarta retrospectively. The number of respondents to the study was 101 geriatric patients who were at risk of metabolic syndrome and experienced hypoglycemic side effects. The data was collected using medical record data. Data analysis of the characteristics of respondents and drug groups was carried out descriptively. The relationship of the subject characteristics and the clinical state of the patient was carried out by using Chi-square. The results saw that the majority of geriatric patients who are at risk of developing metabolic syndrome are women (52.38%) with a normal body mass index (71.43%). More common history of diseases experienced by geriatric patients at risk of metabolic syndrome are diabetes mellitus and hypertension (60,95%) and patients with no complications (67.62%). The history of the disease correlates with the clinical state of the patient in particular cholesterol and triglyceride levels (p<0,05). In addition, complications correlate also with blood pressure values (p<0,05). The most commonly used classes of drugs in geriatric patients at risk of metabolic syndrome are ARB antihypertensive (76.19%), insulin antidiabetics (50,48%), and statin antidislipidemia (41.90%).
References
K. G. M. M. Alberti and P. Z. Zimmet, “Definition , Diagnosis and Classification of Diabetes Mellitus and its Complications Part 1?: Diagnosis and Classification of Diabetes Mellitus Provisional Report of a WHO Consultation,” pp. 539–553, 1998.
L. Kazlauskiene, J. Butnoriene, and A. Norkus, “Metabolic syndrome related to cardiovascular events in a 10-year prospective study,” Diabetol. Metab. Syndr., vol. 7, no. 1, pp. 1–7, 2015, doi: 10.1186/s13098-015-0096-2.
Y. U. Kang et al., “Metabolic Syndrome and Chronic Kidney Disease in an Adult Korean Population?: Results from the Korean National Health Screening,” vol. 9, no. 5, 2014, doi: 10.1371/journal.pone.0093795.
F. E. Li et al., “Sex-based differences in and risk factors for metabolic syndrome in adults aged 40 years and above in Northeast China: Results from the cross-sectional China national stroke screening survey,” BMJ Open, vol. 11, no. 3, pp. 1–10, 2021, doi: 10.1136/bmjopen-2020-038671.
Siti Nur Kholifah, Modul Bahan Ajar Cetak Keperawatan “Keperawatan Gerontik,” Satu. Jaka: Pusat Pendidikan Sumber Daya Manusia Kesehatan, 2016.
M. A. N. Saad, G. P. Cardoso, W. de A. Martins, L. G. C. Velarde, and R. A. da Cruz Filho, “Prevalence of Metabolic Syndrome in Elderly and Agreement among Four Diagnostic Criteri,” Arq. Bras. Cardiol., vol. 102, no. 3, pp. 263–269, 2014, doi: 10.5935/abc.20140013.
C. Wang, “On the Application of Clustering and Classification Techniques to Analyze Metabolic Syndrome Severity Distribution Area and Critical Factors,” 2019.
F. Fenty, W. A, V. DM, and H. P, “METABOLIC SYNDROME AMONG ADULTS IN RURAL AREAS (Sindrom Metabolik pada Dewasa di Daerah Pedesaan),” Indones. J. Clin. Pathol. Med. Lab., vol. 22, no. 3, p. 254, 2018, doi: 10.24293/ijcpml.v22i3.1241.
K. Suastika et al., “Relationship between age and metabolic disorders in the population of Bali,” J. Clin. Gerontol. Geriatr., vol. 2, no. 2, pp. 47–52, 2011, doi: 10.1016/j.jcgg.2011.03.001.
Y. Yi and J. An, “Sex differences in risk factors for metabolic syndrome in the Korean population,” Int. J. Environ. Res. Public Health, vol. 17, no. 24, pp. 1–14, 2020, doi: 10.3390/ijerph17249513.
A. Akrom, E. Darmawan, and N. Maulida, “Factors relate to the hypercreatininemia event of patients at the risk of metabolic syndrome in Jetis I public health center,” Pharmaciana, vol. 7, no. 2, p. 205, 2017, doi: 10.12928/pharmaciana.v7i2.6717.
I. D. Federation, IDF DIABETES ATLAS. Sixth Edition, Belgium: I., vol. 76, no. 7. Brussels, 2014.
L. de O. Comini et al., “Individual and combined components of metabolic syndrome with chronic kidney disease in individuals with hypertension and/or diabetes mellitus accompanied by primary health care,” Diabetes, Metab. Syndr. Obes. Targets Ther., vol. 13, pp. 71–80, 2020, doi: 10.2147/DMSO.S223929.
M. Sihombing and D. H. Tjandrarini, “Faktor Risiko Sindrom Metabolik Pada Orang Dewasa Di Kota Bogor,” Penelit. Gizi dan Makanan (The J. Nutr. Food Res., vol. 38, no. 1, pp. 21–30, 2015, doi: 10.22435/pgm.v38i1.4418.21-30.
F. Yuliani, F. Oenzil, and D. Iryani, “Artikel Penelitian Hubungan Berbagai Faktor Risiko Terhadap Kejadian Penyakit Jantung Koroner Pada Penderita Diabetes Melitus Tipe 2,” vol. 3, no. 1, pp. 37–40, 2014.
IDF, “The IDF consensus worldwide definition of the metabolic syndrome,” 2006.
D. Oktianti, F. N. Dewi, and M. Pujiawati, “Evaluasi penggunaan obat antihipertensi pada pasien diabetes mellitus di RSI Sultan Agung Semarang 2016,” J. Manaj. dan Pelayanan Farm., vol. 7, no. 4, pp. 197–203, 2017.
P. A. James et al., “2014 Evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8),” JAMA - J. Am. Med. Assoc., vol. 311, no. 5, pp. 507–520, 2014, doi: 10.1001/jama.2013.284427.
R. J. Ligthelm, M. Kaiser, and J. Vora, “Insulin Use in Elderly Adults?: Risk of Hypoglycemia and Strategies for Care,” 2012, doi: 10.1111/j.1532-5415.2012.04055.x.
PERKENI, Pedoman Pengelolaan Dislipidemi di Indonesia 2019, Pertama. Jakarta: PB Perkeni, 2019.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Jurnal Sains dan Kesehatan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
